Home How It Works Goals Protocols Lab Tests Peptides Blog About Log In Get Started

GH Secretagogues

MK-677 (Ibutamoren)

MK-677 (ibutamoren) is an orally active, non-peptide ghrelin receptor agonist — the only GH secretagogue that does not require injection. Human RCT data confirm potent GH and IGF-1 stimulation. Important caveats apply: documented glucose elevation risk, investigational drug status, no approved 503A compounding pathway, and widespread grey-market distribution that raises serious product quality concerns. Evidence level: Level II–III (human RCTs in specific populations; not FDA-approved for any indication).

Read this first — regulatory alert

MK-677 has significant regulatory and safety caveats that differ from other GHS compounds.

⚠ Regulatory and Grey-Market Alert

MK-677 is not FDA-approved for any indication. It is classified as an investigational new drug — it has been studied in clinical trials but has never received FDA approval. It is not on any FDA-approved 503A bulk drug substances list and generally cannot be legally compounded or dispensed through standard 503A compounding pharmacy frameworks. Any telehealth program offering MK-677 through 503A channels should be scrutinized for regulatory compliance.

MK-677 is widely sold through online research chemical companies and supplement channels — often marketed as a "research chemical" or with disclaimers that it is "not for human consumption." This grey-market availability represents a serious patient safety concern: these products have no regulatory oversight, no verified pharmaceutical-grade manufacturing, no confirmed identity testing, and no guaranteed dosing accuracy. The fact that a compound is widely available for purchase online does not make it safe, legal for clinical use, or verifiable as authentic.

Mechanism of action

What MK-677 is and how it works — and why it's different.

MK-677 is unique in the GH secretagogue class: it is a non-peptide small molecule, not a peptide. This structural difference is the source of both its most appealing feature (oral bioavailability) and several of its most important clinical distinctions.

Non-Peptide Small Molecule — Orally Active Ghrelin Mimetic

MK-677 (ibutamoren mesylate) is a spiropiperidine compound — a small synthetic molecule that is not structurally related to peptides. While all other GHS compounds discussed on this platform (CJC-1295, ipamorelin, sermorelin, tesamorelin) are peptides that are degraded in the gastrointestinal tract and must be administered by subcutaneous injection, MK-677's small molecule structure allows it to be absorbed through the GI tract after oral ingestion. This pharmacokinetic property makes MK-677 the only GH secretagogue that can be taken as a daily oral capsule or tablet.

Mechanistically, MK-677 binds to the growth hormone secretagogue receptor type 1a (GHS-R1a) — the same ghrelin receptor targeted by ipamorelin — and activates it with high affinity. Ghrelin receptor activation stimulates GH release from the anterior pituitary, raises IGF-1 levels, and activates appetite-stimulating circuits. The oral route and long half-life (~24 hours) of MK-677 produce a sustained, non-pulsatile increase in GH and IGF-1 — in contrast to injectable GHRH analogs and ghrelin mimetics, which produce more discrete GH pulses.

Ghrelin Receptor Agonism — Appetite and GH Stimulation Together

Ghrelin is the body's primary hunger-stimulating hormone, and ghrelin receptor activation has two notable consequences: GH secretion and appetite stimulation. MK-677 activates both. The appetite-stimulating effect of MK-677 is more pronounced than with ipamorelin (which has greater selectivity for GH without the same appetite drive) and is clinically relevant: patients on MK-677 commonly report significantly increased appetite and caloric intake, which can counteract fat-loss goals if dietary intake is not monitored.

The sustained GH elevation produced by MK-677's ~24-hour half-life is mechanistically distinct from the pulsatile GH release produced by GHRH analogs. Whether sustained versus pulsatile GH elevation produces different long-term outcomes has not been definitively evaluated in head-to-head clinical trials. Pituitary somatotroph cells may be subject to different feedback dynamics with sustained versus pulsatile stimulation — a theoretical consideration that supports the preference for more physiologically pulsatile GHS approaches in most clinical programs.

What patients explore it for

Clinical interests — with honest context about risks and regulatory limits.

The clinical interest in MK-677 is driven primarily by its oral availability — a major practical advantage over injectable GHS compounds. The following use cases reflect clinical research interests, not FDA-approved indications.

GH / IGF-1 Axis Stimulation — No Injection Required

MK-677's primary appeal: it activates the GH/IGF-1 axis through a once-daily oral dose rather than daily injections. For patients with needle aversion, logistical challenges with injection protocols, or preference for oral administration, MK-677 is the only compound in the GHS class that offers this modality. The GH and IGF-1 stimulation is well-documented in human RCTs — the mechanism is real and the pharmacodynamic effect has been measured and published.

Elderly Frailty and Muscle Preservation

Multiple human clinical trials evaluated MK-677 in elderly populations specifically for its potential to reverse age-related GH decline and muscle loss. The Chapman 1996 RCT (PMID: 8954023) in elderly subjects demonstrated significant GH and IGF-1 elevation. The evidence in elderly frailty contexts includes some of the more meaningful human trial data available for this compound class, though a congestive heart failure signal in one frailty trial (Grinspoon et al.) resulted in early termination — a significant safety concern for cardiac patients.

Sleep Architecture Enhancement

MK-677 has been studied for its effects on sleep architecture. Early clinical research showed that MK-677 significantly increased REM sleep time and slow-wave sleep (Stage 4) in both young and elderly subjects — effects that correlate with the role of ghrelin and GH in sleep regulation. Some patients explore MK-677 primarily for sleep quality improvement. These sleep effects are among the more interesting human findings for MK-677, though the glucose and appetite effects must be weighed in any clinical decision.

Body Composition — Muscle and Fat

Human studies of MK-677 have shown increases in lean body mass and fat mass changes consistent with GH axis activation. However, the appetite-stimulating effect of ghrelin receptor activation can increase caloric intake, potentially offsetting fat-loss goals if dietary discipline is not maintained. MK-677 may support lean mass preservation in the context of a calorie-controlled protocol, but its net body composition effect depends heavily on concurrent dietary management.

Bone Density Support

GH and IGF-1 play established roles in bone formation and mineralization. MK-677 trials in elderly populations have shown improvements in bone mineral density markers, with some studies demonstrating reduced bone resorption markers. This finding has generated interest in MK-677 for osteoporosis prevention in at-risk populations — though no clinical trial has established MK-677 as an effective osteoporosis treatment, and FDA approval for this use does not exist.

Recovery and GH-Mediated Tissue Repair

The same GH-mediated connective tissue synthesis and cellular repair benefits explored with injectable GHS compounds apply to MK-677 in principle, since GH and IGF-1 elevation through any GHS mechanism activates similar downstream pathways. The oral administration route makes MK-677 appealing for patients exploring GH axis support for recovery purposes who prefer to avoid injections — subject to the glucose, appetite, and regulatory caveats discussed throughout this page.

Evidence summary

Real human RCT data — with real documented risks.

MK-677 has a larger human clinical trial dataset than CJC-1295/ipamorelin (outside of ipamorelin's preclinical selectivity data) but smaller and more limited populations than tesamorelin's Phase 3 program. The evidence is real and the GH/IGF-1 stimulation is documented — as are the glucose risks. All PMIDs below are verified against PubMed.

MK-677 in Healthy Elderly — Landmark RCT

PMID: 8954023 · Chapman et al., J Clin Endocrinol Metab 1996 · Evidence: Level II (RCT in elderly subjects)

This landmark RCT in healthy elderly subjects (mean age ~65) is the most frequently cited human pharmacodynamic trial for MK-677. Daily oral MK-677 25 mg for 2 weeks increased mean 24-hour GH concentration by 97% and raised serum IGF-1 from 141 to 265 mcg/L — into the normal range for young adults. The GH and IGF-1 stimulation was clinically substantial and unambiguous. The study also documented a significant and important adverse finding: fasting glucose rose from 5.4 to 6.8 mmol/L at 4 weeks — approaching pre-diabetic thresholds. This glucose elevation is the most important documented safety concern with MK-677 and must be disclosed to all patients considering this compound.

MK-677 and Sleep Architecture — Human Data

Thorner et al., multiple publications; additional references available · Evidence: Level II–III (small human trials)

Early human studies of MK-677 — including trials in young adults and elderly subjects — documented significant increases in REM sleep duration and slow-wave (Stage 4) sleep time, consistent with the role of ghrelin signaling and GH secretion in sleep architecture. In some trials, elderly subjects who received MK-677 showed improvements in sleep quality that correlated with GH pulse increases. These sleep architecture findings represent some of the more compelling evidence for non-GH-axis-stimulation benefits of MK-677, though trials were small and short-term.

MK-677 in Frailty — Congestive Heart Failure Signal

Grinspoon et al. — older frailty trial; referenced in multiple GHS reviews · Evidence: Level II (RCT, early termination)

A clinical trial evaluating MK-677 in elderly patients with hip fractures was terminated early following reports of worsening congestive heart failure (CHF) symptoms in a subset of participants. This finding — while based on a specific, high-risk elderly population — is an important safety reference point for MK-677 in patients with pre-existing cardiovascular disease or CHF. The mechanism likely involves fluid retention associated with GH elevation combined with the cardiovascular stress of the trial population. Cardiac patients require explicit risk-benefit evaluation before any GH-stimulating compound, and MK-677's documented CHF signal makes this particularly important.

GHS Systematic Review — MK-677 in Context

DOI: 10.21037/tau.2019.11.30 · Sinha et al. 2020 · Evidence: Level III (systematic review)

This systematic review synthesized evidence for multiple GHS compounds including ibutamoren. It confirmed that MK-677 reliably elevates GH and IGF-1 in human trials across multiple populations, with the associated body composition effects consistent with GH axis activation. The review also highlighted the glucose elevation concern and the absence of long-term safety data for chronic oral MK-677 use. The conclusion — "a paucity of data examining long-term clinical effects currently limits our understanding" — applies with particular force to MK-677 given its investigational status and the absence of any approved clinical indication.

Evidence Framing — What MK-677's Data Does and Doesn't Establish

Editorial summary — not a single study

MK-677 human trial data establish: (1) potent oral GH and IGF-1 stimulation in elderly and adult subjects; (2) documented fasting glucose elevation that is clinically significant and must be monitored; (3) a congestive heart failure signal in a frailty population; (4) sleep architecture benefits in small trials. What MK-677 data do not establish: long-term safety (beyond weeks to months); efficacy for any FDA-approvable indication; a favorable risk-benefit profile across diverse patient populations without careful clinical screening. The compound's real evidence base should be evaluated alongside its significant regulatory and grey-market concerns.

Dosing context — educational only

What clinical research protocols used — with critical caveats.

⚠ EDUCATIONAL ONLY — No FDA-Approved Protocol Exists. Standard 503A Programs Cannot Legally Dispense MK-677.

MK-677 is not FDA-approved for any indication. No FDA-approved dosing protocol exists. MK-677 is not on the FDA-approved 503A bulk drug substances list and cannot be legally compounded or dispensed through standard 503A clinical compounding pharmacy frameworks. The dosing information below describes what was used in published clinical research studies — for informational context only. It is not a prescription, recommendation, or endorsement of MK-677 use. Any patient considering MK-677 should discuss its regulatory status, grey-market sourcing risks, and documented safety profile explicitly with a licensed clinician.

Research Trial Dosing — Documented in Published Studies

Human clinical trials have primarily evaluated oral MK-677 at doses of 10 mg, 25 mg, and 50 mg daily. The Chapman 1996 elderly RCT (PMID: 8954023) used 25 mg daily. Higher doses have been evaluated in other trials with dose-dependent increases in GH/IGF-1 elevation and adverse effect frequency. The 25 mg dose is the most studied and most frequently referenced in clinical discussion contexts. MK-677's ~24-hour half-life supports once-daily oral dosing with relatively stable plasma levels.

Monitoring Considerations

Given MK-677's documented fasting glucose elevation, fasting blood glucose and HbA1c should be monitored at baseline and regularly during any MK-677 use. IGF-1 monitoring is standard — as with all GHS protocols — to confirm GH axis response and prevent supraphysiologic IGF-1 levels. Patients with pre-diabetes or metabolic syndrome are at elevated risk for clinically significant glucose worsening. Cardiac patients require evaluation for fluid retention and heart failure symptom monitoring. The full monitoring protocol should be determined by the prescribing clinician.

Safety & contraindications

Documented risks and why MK-677 requires the most cautious clinical approach in the GHS class.

MK-677 has documented adverse effects in human clinical trials — not just theoretical concerns. The glucose elevation and CHF signal are real findings from published research. This page presents these risks honestly because patient safety depends on accurate information.

Fasting Glucose Elevation — Documented in RCT

The Chapman 1996 RCT (PMID: 8954023) showed fasting glucose rose from 5.4 to 6.8 mmol/L in healthy elderly subjects on MK-677 25 mg daily for 4 weeks. This elevation — into the pre-diabetic threshold — is the most important documented safety concern unique to MK-677 among GHS compounds. Patients with pre-existing diabetes, pre-diabetes, insulin resistance, or metabolic syndrome face materially elevated risk. Fasting glucose and HbA1c monitoring are essential for any clinical program involving MK-677. This glucose effect is more pronounced than with tesamorelin (which showed no clinically meaningful glucose change in Phase 3 trials) or GHRH analogs generally.

Congestive Heart Failure Signal

A frailty trial in elderly patients with hip fractures was terminated early following congestive heart failure symptom worsening in a subset of participants. This finding elevates the risk profile for MK-677 in patients with pre-existing heart failure, significant cardiovascular disease, or cardiomyopathy. The mechanism likely involves GH-mediated fluid retention — GH causes sodium and water retention that can exacerbate heart failure physiology in susceptible patients. MK-677 should not be used in patients with active congestive heart failure without explicit cardiologist consultation.

Appetite Stimulation — Significant and Expected

Ghrelin receptor activation stimulates appetite — this is a fundamental and well-characterized physiological effect of GHS-R1a agonism. MK-677's appetite-stimulating effect is more pronounced than ipamorelin's (which has greater GH selectivity relative to appetite stimulation). Patients report significantly increased hunger and food cravings, particularly for calorie-dense foods. This effect can meaningfully increase caloric intake and counteract fat-loss goals if dietary management is not vigilant. It is not a side effect to minimize — it is a direct pharmacological consequence of the mechanism.

Fluid Retention and Edema

GH promotes sodium and water retention. Peripheral edema, bloating, and fluid retention are commonly reported with MK-677, particularly during initiation. This is consistent with the class-wide GHS adverse effect profile — but MK-677's sustained (rather than pulsatile) GH elevation may produce a more persistent fluid retention signal than shorter-acting injectable compounds. Patients with hypertension or cardiac conditions should be monitored for fluid balance.

Active Malignancy — Class-Wide Concern

As with all GHS compounds, the mitogenic activity of GH and IGF-1 is a primary theoretical safety concern in patients with active cancer or significant personal history of hormone-sensitive malignancy. MK-677's sustained IGF-1 elevation — from its ~24-hour half-life and continuous receptor activation — may be of particular relevance here compared to more pulsatile injectable GHS protocols. Oncology consultation is required before any GH-stimulating compound in patients with cancer history.

Grey-Market Product Quality Risks

MK-677 is widely sold through online research chemical companies with no pharmaceutical-grade manufacturing oversight. Products purchased through these channels may be contaminated, mislabeled, adulterated with other compounds, inaccurately dosed, or not contain MK-677 at all. Independent laboratory testing of MK-677 products purchased through grey-market channels has identified significant batch-to-batch variability and contamination. This is not a hypothetical risk — it is a documented, real-world patient safety concern with any compound distributed outside regulated pharmaceutical channels.

Regulatory status — mid-2026

Investigational drug status, no 503A pathway, and the grey-market problem explained.

Investigational New Drug — No FDA Approval, No 503A Pathway

MK-677 is classified as an investigational new drug — it has been studied in clinical trials by multiple pharmaceutical sponsors but has never received FDA approval for any indication. Multiple IND applications for MK-677 have been explored across indications including growth hormone deficiency, frailty, and metabolic conditions; none resulted in an approved NDA or BLA.

Critically, MK-677 is not on the FDA's approved 503A bulk drug substances list — and being an investigational drug makes it even less likely to qualify for compounding under standard 503A frameworks. Under FDA regulations, a drug that is the subject of an approved or pending NDA may not be compounded under 503A. Standard 503A compounding pharmacies cannot legally dispense MK-677 to patients. Any clinical program purporting to offer compounded MK-677 should be evaluated carefully for regulatory compliance.

The Grey-Market Problem — Explicitly Explained

MK-677 is sold widely online through research chemical companies, supplement distributors, and grey-market health sites — often marketed with disclaimers like "for research purposes only" or "not for human consumption." These disclaimers do not change the reality of how MK-677 is used by many consumers. Grey-market MK-677 products: have no FDA manufacturing oversight; cannot be verified for identity, purity, or dose accuracy; are sold without clinician involvement; and carry no accountability for adverse effects. Patients who use grey-market MK-677 without clinical supervision are conducting unmonitored self-experimentation with an investigational compound — a fundamentally different risk profile from using a clinician-monitored, pharmacy-compounded, regulated GHS peptide.

WADA Status — Prohibited in Competitive Sports

MK-677 is prohibited under the WADA Prohibited List — classified under growth hormone secretagogues and other peptide hormones. Testing methods for MK-677 in urine have been developed. Athletes in sanctioned competition who use MK-677 — from any source, clinical or grey-market — are at risk of anti-doping violations and the consequences thereof. Non-athletes in clinical settings are not subject to WADA regulations, but the prohibition underscores the compound's recognition as a performance-relevant GH-stimulating agent.

MK-677 is not FDA-approved, not on any 503A approved bulks list, and classified as an investigational drug. Standard telehealth compounding programs cannot legally dispense it. Grey-market sourcing carries unacceptable product quality risks. If you are interested in oral GH axis support, discuss with your licensed clinician whether any legal alternative — including clinical trial participation — may be appropriate for your situation. Last reviewed: May 2026.

FAQ

Common questions about MK-677 — answered honestly.

Is MK-677 FDA-approved?

No. MK-677 (ibutamoren) is not FDA-approved for any indication. It is classified as an investigational drug — studied in clinical trials but never completing the approval process. It is not on any FDA-approved 503A bulk drug substances list and cannot be legally dispensed through standard compounding pharmacy frameworks.

Why is it sold everywhere online if it's not approved?

MK-677 is widely sold through research chemical companies and supplement channels as a "research chemical not for human consumption." This grey-market distribution exists outside regulated pharmaceutical channels with no manufacturing oversight, purity verification, or dose accuracy guarantee. Widespread availability does not equal legal clinical use or product safety.

Does MK-677 actually work?

The GH and IGF-1 stimulation is real — documented in human RCTs including the Chapman 1996 trial (PMID: 8954023), which showed 97% GH increase and significant IGF-1 elevation with oral MK-677. The mechanism is pharmacologically sound. The documented adverse effects — fasting glucose elevation, appetite stimulation, fluid retention, and a CHF signal in frailty populations — are equally real and must be weighed alongside the efficacy data.

What is the biggest risk?

The most documented safety concern specific to MK-677 is fasting glucose elevation: the Chapman 1996 RCT showed fasting glucose approaching pre-diabetic thresholds in healthy elderly subjects. A congestive heart failure signal in a frailty trial is also relevant for cardiac patients. Appetite stimulation that may increase caloric intake is a practical concern for patients with fat-loss goals. Grey-market product quality risks apply to all unsourced MK-677 purchases.

Can my doctor prescribe MK-677?

Not through standard 503A compounding channels. MK-677 is an investigational drug and is not on the FDA-approved 503A bulk drug substances list. A clinician cannot issue a prescription for compounded MK-677 through a standard 503A pharmacy. If you are interested in GH axis support through an oral route, discuss with a licensed clinician whether any legal clinical trial access, alternative compound, or other approach may be appropriate.

How is MK-677 different from ipamorelin?

Both activate the ghrelin receptor (GHS-R1a). Ipamorelin is a peptide requiring subcutaneous injection; MK-677 is a small molecule taken orally. Ipamorelin demonstrated GH selectivity without significant cortisol or glucose effects in preclinical studies; MK-677 has a documented glucose elevation signal in human trials. Ipamorelin is used in 503A clinical programs (regulatory status evolving); MK-677 cannot be dispensed through standard 503A frameworks.

Is MK-677 banned in sports?

Yes. MK-677 is prohibited in competitive sports under the WADA Prohibited List. Athletes in sanctioned competition — including recreational events with WADA-affiliated anti-doping oversight — are at risk of a doping violation for any MK-677 use, regardless of source. Testing methods for MK-677 in urine have been developed and validated.

Informational only. Content on this page is for educational purposes and does not constitute medical advice. MK-677 is not FDA-approved for any indication, not on any approved 503A bulk drug substances list, and is an investigational drug. This platform and its clinical partners do not dispense MK-677. All information is educational — patients should discuss their full clinical situation with a licensed clinician before considering any GHS compound. Last reviewed: May 2026.

Related

Legal alternatives and related compounds to explore.

CJC-1295 / Ipamorelin

The most widely used GHS combination in telehealth — dual-pathway GH amplification via GHRH analog and selective ghrelin receptor agonist. Ipamorelin provides ghrelin receptor agonism with significantly better glucose selectivity than MK-677. Administered by subcutaneous injection.

Read the CJC-1295/Ipamorelin Page

Tesamorelin

The only FDA-approved GH secretagogue for adult body composition. Phase 3 RCT evidence, no meaningful glucose worsening, and the strongest regulatory and evidence foundation in the GHS class. Available by prescription for HIV-associated lipodystrophy; off-label evaluation by clinician.

Read the Tesamorelin Page

Sermorelin

Historical FDA approval (Geref®), decades of clinical safety record, available through 503A compounding. A well-established alternative for patients interested in GH axis support through a clinically supervised, legally available pathway.

Read the Sermorelin Page

GH Secretagogues — Category Overview

Understand the full GHS compound class — all four compounds side by side, with evidence levels and regulatory status compared — before your clinical consultation.

Back to GHS Hub

Start a Clinical Evaluation

A licensed clinician reviews your full health history, labs, and goals — and can help you understand which GHS compounds are legally available and clinically appropriate for your situation, versus which carry regulatory and safety concerns that make them inappropriate.

Start Your Intake

Want GH axis support without the regulatory and quality risks?

Legal GHS alternatives — including one with FDA approval — may address your goals with a better risk profile.

A licensed clinician evaluates your IGF-1, glucose status, cardiovascular history, and clinical goals to determine which GH secretagogue protocol is legally available and appropriate for you.

Start Your Intake Back to GH Secretagogues